Clinical Trial Update: Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants. [Phase 1]

View source ↗

Summary

Phase 1 study evaluating ALXN1840's effect on metabolism of a CYP2C9 substrate in healthy participants completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wilson Disease

Drugs mentioned

• ALXN1840 (ALXN1840)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Wilson Disease | Phase 1 | Status: COMPLETED | Results posted: 2023-08-21